RELIANCE 研究中 relmacabtagene autoleucel 治疗复发/难治性滤泡性淋巴瘤的两年随访

Relmacabtagene autoleucel (relma-cel) demonstrated significant clinical outcomes for 3 lines of treatment for relapsed or refractory (R/R) follicular lymphoma (FL) in the RELIANCE study. The primary end-point was the complete response rate (CRR) at 3 months. Key secondary end-points included the duration of response (DOR), progression-free survival (PFS), overall survival (OS) and frequency/severity of adverse events (AEs). Relma-cel-treated patients (N = 28) had a median age of 54 years (range: 36-71 years), and more than 60% of the patients received 3 lines of prior systemic therapies. The median follow-up was 24. 4 months. As previously reported, in the primary analyses set (n = 27), the 3-month CRR was 85.

2% and the 3-month overall response rate was 100. 0%. The median DOR, PFS and OS were not reached. As updated in this article, the estimated 2-year PFS and OS rates were 80. 3% and 100% respectively. During the 90-day treatment-emergent period (N = 28), no patients had cytokine release syndrome of grade 3, and neurological toxicity of grade 3 occurred in only one patient treated with 100 10 6 chimeric antigen receptor T cells.

Neutropenia (39. 3%) was the most common grade 3 treatment-emergent adverse event. There were no AEs leading to death. Relma-cel demonstrated durable remissions and manageable safety without new safety signals during the 2-year follow-up in patients with R/R FL (ClinicalTrials. gov, NCT04089215).